Real-world treatment attrition rates in advanced esophagogastric cancer.

ABSTRACT:

Background

Over the last decade, multiple agents have demonstrated efficacy for advanced esophagogastric cancer (EGC). Despite the availability of later lines of therapy, there remains limited real-world data about the treatment attrition rates between lines of therapy.

Aim

To characterize the use and attrition rates between lines of therapy for patients with advanced EGC.

Methods

We identified patients who received at least one cycle of chemotherapy for advanced EGC between July 1, 2017 and July 31, 2018 across six regional centers in British Columbia (BC), Canada. Clinicopathologic, treatment, and outcomes data were extracted.

Results

Of 245 patients who received at least one line of therapy, median age was 66 years (IQR 58.2-72.3) and 186 (76%) were male, Ea

SUBMITTER: Tsang ES 

PROVIDER: S-EPMC7584053 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature